Dehydrated Alcohol Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: ≥99% ethyl alcohol
Reference Brands: ABLYSINOL (USA)
Category:
Heart Disorder
Dehydrated Alcohol is available in Injection
and strengths such as ≥99% ethyl alcohol.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Dehydrated Alcohol is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Dehydrated Alcohol can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
ABLYSINOL® is a sterile dehydrated alcohol (ethyl alcohol) injection indicated for the treatment of adults with symptomatic hypertrophic obstructive cardiomyopathy (HOCM) who are not suitable candidates for surgical myectomy. It works by inducing a controlled cardiac septal infarction, reducing obstruction in the left ventricular outflow tract and thereby improving exercise capacity and relieving symptoms such as shortness of breath and chest discomfort. The active component, dehydrated alcohol (≥99%), is delivered via intra-arterial injection into the septal branches of the coronary artery under the guidance of an experienced interventional cardiologist. This procedure creates localized tissue necrosis in the hypertrophied septum, which leads to a reduction in septal thickness and improvement in cardiac function over time. ABLYSINOL is supplied in single-dose vials or ampules of 1 mL and 5 mL, ensuring precise dosing for controlled administration. The product is manufactured by BPI Labs, LLC in the United States and is intended for use only in specialized cardiac centers with appropriate monitoring and supportive measures, due to potential risks such as arrhythmias or transient heart block. ABLYSINOL provides a minimally invasive therapeutic option for patients with HOCM who cannot undergo surgery.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing